Contract win for new stroke study

New therapeutic area, broadening IXICO’s neurological footprint

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has executed a contract to provide neuroimaging services for a new clinical trial for acute ischemic stroke with its largest pharma client.

The contract win reflects a further broadening of IXICO’s neurological footprint into a new therapeutic area with this client and demonstrates that the Company continues to build momentum in its growth strategy of further diversification into new therapeutic areas. Ischemic stroke is caused by a blockage cutting off the blood supply to the brain. This is the most common form of stroke and accounts for approximately 85% of cases. The new Phase II acute ischemic stroke trial, will be conducted across 50 sites in North America and Europe and is worth in excess of US$0.5m over 35 months.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "We are delighted to be awarded this new study by our existing pharma client. Having singularly focused on neurological disorders since our inception in 2004, IXICO has a long and established history of delivering advanced neuroimaging solutions to the biopharmaceutical sponsors. This new contract demonstrates our continually expanding footprint and deepening expertise within IXICO’s proven specialist domain.

 

For further information please contact:

Walbrook PR Ltd

+44 (0)20 7933 8780

Paul McManus / Lianne Cawthorne /

IXICO@walbrookpr.com

Alice Woodings

 

 


Date: 28/04/2021